These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years. Madsen MC; van Dijk D; Wiepjes CM; Conemans EB; Thijs A; den Heijer M J Clin Endocrinol Metab; 2021 May; 106(6):1710-1717. PubMed ID: 33599731 [TBL] [Abstract][Full Text] [Related]
3. Erythrocytosis in Gender-Affirming Care With Testosterone. Porat AT; Ellwood M; Rodina M; Dianat S Ann Fam Med; 2023; 21(5):403-407. PubMed ID: 37748907 [TBL] [Abstract][Full Text] [Related]
4. Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy. Krishnamurthy N; Slack DJ; Kyweluk M; Cullen O; Kirkley J; Safer JD J Clin Endocrinol Metab; 2024 Apr; 109(5):1285-1290. PubMed ID: 38011684 [TBL] [Abstract][Full Text] [Related]
5. Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis. Aghazadeh M; Pastuszak AW; Johnson WG; McIntyre MG; Hsieh TM; Lipshultz LI J Urol; 2015 Jul; 194(1):160-5. PubMed ID: 25596360 [TBL] [Abstract][Full Text] [Related]
6. Erythrocytosis Following Testosterone Therapy. Ohlander SJ; Varghese B; Pastuszak AW Sex Med Rev; 2018 Jan; 6(1):77-85. PubMed ID: 28526632 [TBL] [Abstract][Full Text] [Related]
7. Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review. Okano SHP; Braga GC; Cantelli DAL; Filho LASP; Brito LGO; Lara LADS Andrology; 2024 Jul; ():. PubMed ID: 39011565 [TBL] [Abstract][Full Text] [Related]
8. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. Velho I; Fighera TM; Ziegelmann PK; Spritzer PM Andrology; 2017 Sep; 5(5):881-888. PubMed ID: 28709177 [TBL] [Abstract][Full Text] [Related]
9. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. Jones SD; Dukovac T; Sangkum P; Yafi FA; Hellstrom WJ Sex Med Rev; 2015 Apr; 3(2):101-112. PubMed ID: 27784544 [TBL] [Abstract][Full Text] [Related]
10. Hematocrit Response and Risk Factors for Significant Hematocrit Elevation with Implantable Testosterone Pellets. Hayden RP; Bennett NE; Tanrikut C J Urol; 2016 Dec; 196(6):1715-1720. PubMed ID: 27287525 [TBL] [Abstract][Full Text] [Related]
11. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Ip FF; di Pierro I; Brown R; Cunningham I; Handelsman DJ; Liu PY Eur J Endocrinol; 2010 Feb; 162(2):385-90. PubMed ID: 19903801 [TBL] [Abstract][Full Text] [Related]
12. Testosterone therapy and secondary erythrocytosis. White J; Petrella F; Ory J Int J Impot Res; 2022 Nov; 34(7):693-697. PubMed ID: 34987178 [TBL] [Abstract][Full Text] [Related]
14. Letter to the Editor From Laidlaw et al: "Erythrocytosis in a Large Cohort of Transgender Men Using Testosterone: A Long-term Follow-up Study on Prevalence, Determinants, and Exposure Years". Laidlaw MK; Van Mol A; Van Meter Q; Hansen JE J Clin Endocrinol Metab; 2021 Nov; 106(12):e5275-e5276. PubMed ID: 34297088 [No Abstract] [Full Text] [Related]
15. Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone. Oakes M; Arastu A; Kato C; Somers J; Holly HD; Elstrott BK; Dy GW; Kohs TCL; Patel RR; McCarty OJT; DeLoughery TG; Milano C; Raghunathan V; Shatzel JJ Thromb Res; 2021 Nov; 207():96-98. PubMed ID: 34592628 [TBL] [Abstract][Full Text] [Related]
16. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. Fernández-Balsells MM; Murad MH; Lane M; Lampropulos JF; Albuquerque F; Mullan RJ; Agrwal N; Elamin MB; Gallegos-Orozco JF; Wang AT; Erwin PJ; Bhasin S; Montori VM J Clin Endocrinol Metab; 2010 Jun; 95(6):2560-75. PubMed ID: 20525906 [TBL] [Abstract][Full Text] [Related]
17. Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases. Motta G; Zavattaro M; Romeo F; Lanfranco F; Broglio F J Clin Endocrinol Metab; 2019 Mar; 104(3):819-822. PubMed ID: 30395251 [TBL] [Abstract][Full Text] [Related]
18. Prescription Patterns and Testosterone Concentrations Achieved With AndroForte 5% Testosterone Cream in Transgender and Gender Diverse Individuals. Nolan BJ; Zwickl S; Locke P; Simpson S; Li L; Zajac JD; Cheung AS J Sex Med; 2022 Jun; 19(6):1049-1054. PubMed ID: 35365401 [TBL] [Abstract][Full Text] [Related]
19. Management of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide. Agrawal P; Singh SM; Kohn T Eur Urol Focus; 2023 Jan; 9(1):20-21. PubMed ID: 36335038 [TBL] [Abstract][Full Text] [Related]
20. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. Gordeuk VR; Key NS; Prchal JT Haematologica; 2019 Apr; 104(4):653-658. PubMed ID: 30872370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]